Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Thoracic 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 1Solid Tumor 1Pancreatic Neoplasms 1Melanoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Camurati-Engelmann Syndrome 1Breast Neoplasms 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 313atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × LY3300054 × Clear all
NCT02937272 2026-04-03

A Study of LY3200882 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
223 enrolled

Camurati-Engelmann Syndrome

NCT02791334 2024-09-27

PACT

Eli Lilly and Company

Phase 1 Completed
164 enrolled
BreastDermatologicGastrointestinal

Breast Neoplasms, Melanoma, Pancreatic Neoplasms

NCT03099109 2023-10-17

A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors

Eli Lilly and Company

Phase 1 Completed
209 enrolled
Other solid neoplasm

Solid Tumor

NCT03343613 2020-06-09

A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
60 enrolled
BreastGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡